(Q44909810)

7 December 2017

Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients (English)

1 reference

7 December 2017

0 references

1 reference

2

1 reference

7 December 2017

12

1 reference

7 December 2017

Ricart E

1

1 reference

7 December 2017

Novella MT

3

1 reference

7 December 2017

Ortiz J

4

1 reference

7 December 2017

Sàbat M

5

1 reference

7 December 2017

Kolle L

6

1 reference

7 December 2017

Sola-Vera J

7

1 reference

7 December 2017

Miñana J

8

1 reference

7 December 2017

Dedéu JM

9

1 reference

7 December 2017

Gómez C

10

1 reference

7 December 2017

Barrio JL

11

1 reference

7 December 2017

1 April 2000

1 reference

7 December 2017

Journal of Hepatology

1 reference

7 December 2017

32

1 reference

7 December 2017

4

1 reference

7 December 2017

596-602

1 reference

Problems of bacterial infection in patients with liver disease

7 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

A prospective study of bacterial infections in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Polymorphonuclear cell count response and duration of antibiotic therapy in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: a prospective study of twenty-seven cases in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Pharmacokinetics of amoxycillin/clavulanic acid in serum and ascitic fluid in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Selective intestinal decontamination prevents spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Hospital-acquired bacterial infections in patients with cirrhosis undergoing selective intestinal decontamination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Experience with cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Early microbiologic diagnosis of spontaneous bacterial peritonitis with BacT/ALERT

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Spontaneous bacterial peritonitis: an explosion of information

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980221-4

7 January 2021

10.1016/S0168-8278(00)80221-4

Identifiers

DOI

1 reference

7 December 2017

1 reference